HEARTMATE 3™ LVAD WITH FULL MAGLEV™ FLOW TECHNOLOGY

THEIR FUTURE STARTS WITH YOU
HEARTMATE 3™ LVAD DELIVERS UNPRECEDENTED1 SURVIVAL AND SAFETY OUTCOMES**1

In the MOMENTUM 3 trial, the largest LVAD trial ever conducted,*** the HeartMate 3 LVAD demonstrated at 2 years:

83% SURVIVAL1
10% STROKE1
1% THROMBOSIS†1

The highest published 2-year survival rate and the lowest published stroke and thrombosis rates for continuous-flow LVADs1-5

HeartMate 3 LVAD outcomes made possible by Full MagLev™ Flow Technology.

NOW APPROVED FOR DESTINATION THERAPY

The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure.

LANDMARK SURVIVAL WITH HEARTMATE 3™ LVAD

NOW COMPARABLE TO TRANSPLANT SURVIVAL AT 2 YEARS14

Now comparable to transplant survival at 2 years14

HeartTransplant68%
HeartMate II™ LVAD (2018)66%
HeartMate II LVAD (2017)66%
OMM (2017)34%
HeartMate XVE (2009)24%

‡ OMM = Optimal Medical Management.
Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only. Please refer to the HeartMate II and HeartMate 3 LVAD Instructions for Use about indications, contraindications, adverse events, warnings, and precautions.

UNPRECEDENTED SURVIVAL AT 2 YEARS1

83%

SUPERIOR EVENT-FREE SURVIVAL AT 2 YEARS (PRIMARY ENDPOINT)†††1

78%
EXCELLENT SAFETY PROFILE

LOWEST PUBLISHED STROKE AND THROMBOSIS RATES FOR CONTINUOUS-FLOW LVADs: 1–3

<table>
<thead>
<tr>
<th>OUTCOMES MADE POSSIBLE BY FULL MAGLEV™ FLOW TECHNOLOGY</th>
</tr>
</thead>
</table>

**HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY**

Full MagLev Flow Technology maintains gentle blood handling to minimize complications and reduce hemocompatibility-related adverse events.

- **Fully levitated, self-centering rotor** that does not require hydrodynamic or mechanical bearings
- **Large, consistent blood flow pathways** to reduce shear stress
- **Intrinsic pulsatility** to reduce blood stasis and minimize thrombus

<table>
<thead>
<tr>
<th>MOMENTUM 3 2018</th>
<th>ENDURANCE 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeartMate 3™ LVAD (n = 189)</td>
<td>HeartMate II™ LVAD (n = 172)</td>
</tr>
<tr>
<td>Stroke (% / EPPY)</td>
<td>Stroke (% / EPPY)</td>
</tr>
<tr>
<td>10.1% / 0.08</td>
<td>19.2% / 0.18</td>
</tr>
</tbody>
</table>

| HeartMate II LVAD (n = 296) | HeartMate II LVAD (n = 149) |
| Stroke (% / EPPY) | Stroke (% / EPPY) |
| 29.7% / 0.29 | 12.1% / 0.09 |

**HEARTMATE 3 LVAD GASTROINTESTINAL BLEEDING (27%) IS SIMILAR TO OTHER LVADs, WHILE MAINTAINING MINIMAL PUMP THROMBOSIS.**

<table>
<thead>
<tr>
<th>MOMENTUM 3 2018</th>
<th>ENDURANCE 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeartMate 3 LVAD (n = 190)</td>
<td>HeartMate II LVAD (n = 176)</td>
</tr>
<tr>
<td>Pump Thrombosis (%)</td>
<td>Pump Thrombosis (%)</td>
</tr>
<tr>
<td>1.1%</td>
<td>15.7%</td>
</tr>
</tbody>
</table>

| HeartMate II LVAD (n = 295) | HeartMate II LVAD (n = 149) |
| Pump Thrombosis (%) | Pump Thrombosis (%) |
| 6.4% | 10.7% |

*HeartMate 3 LVAD stroke rates decreased after 6 months, with a 0.04 EPPY from 6 months through 2-year follow-up.

EPPY = Events Per Patient Year.

*Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables.

Not a head-to-head comparison. Data presented for informational purposes only. Please refer to the HeartMate II and HeartMate 3 LVAD Instructions for Use about indications, contraindications, adverse events, warnings, and precautions.
MAKING A MEANINGFUL DIFFERENCE IN PATIENTS’ LIVES

**SIGNIFICANT IMPROVEMENT IN NEW YORK HEART ASSOCIATION (NYHA) FUNCTIONAL CLASS¹**

78% of patients improved from NYHA Class IIIIB/IV at baseline to NYHA Class I/II by 6 months, with sustained improvement of 79% of patients through 2 years ($P<0.0001$).

**SIGNIFICANT INCREASE IN 6-MINUTE WALK DISTANCE¹**

<table>
<thead>
<tr>
<th>Time</th>
<th>Distance (m)</th>
<th>Difference (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 MONTHS</td>
<td>154</td>
<td>2X INCREASE IN DISTANCE</td>
</tr>
<tr>
<td>24 MONTHS</td>
<td>308</td>
<td>2X INCREASE IN DISTANCE</td>
</tr>
</tbody>
</table>

Note: One football field = 91 m (100 yards)

**IMPROVED QUALITY OF LIFE¹**

**28 POINT IMPROVEMENT** in KCCQ overall summary score at 3 months was sustained out to 2 years ($P<0.0001$).

**REDUCTION IN REHOSPITALIZATIONS⁹**

- **8.3 FEWER** hospital days
- **51% REDUCTION** in average cumulative cost per patient-year

KCCQ = Kansas City Cardiomyopathy Questionnaire.

HEARTMATE 3™ LVAD SYSTEM

A better experience for clinicians and patients

**HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY**

HeartMate 3 LVAD

Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body

**Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body**

**Pocket controller**

Powers and controls the LVAD and is small enough to fit in a pocket. Includes emergency backup battery

**Mobile Power Unit (MPU)**

Plug-in power source

**Heart Mate 3 LVAD**

Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body

**Batteries**

Provide up to 77 hours of uninterrupted power

**Modular driveline**

Facilitates simple replacement of externalized portion

**Pocket controller**

Powers and controls the LVAD and is small enough to fit in a pocket. Includes emergency backup battery

**Mobile Power Unit (MPU)**

Plug-in power source
References:

Abbott
One St. Jude Medical Dr., St. Paul, MN 55177 USA, Tel: 1 651 756 2000
HeartMate3.com
St. Jude Medical is now Abbott.

Rx Only

Important Safety Information

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure.

Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or device thrombosis.

Abbott

© 2018 Abbott. All Rights Reserved.